RECIST was developed in 2000 by the National Cancer Institute, European Organization for Research and Treatment of Cancer, and National Cancer Institute of Canada, with revision to RECIST 1.1 in 2009 ...

Dr. Bernd Pichler is a distinguished pioneer in preclinical and translational imaging, renowned for his groundbreaking work in multimodal imaging and imaging tracer development. As chair of the ...

Large language models have become enormously powerful tools for summarizing existing knowledge and generating text, figures, and references for scientific publications. This power can be abused to ...

Cytokines are small proteins that directly regulate immune cell proliferation and signaling. An improved understanding of cytokine expression in specific microenvironments provides critical insights ...

Fibroblast activation protein (FAP) has become an attractive target for diagnosis and therapy, and a series of FAP inhibitor (FAPI)–based radiotracers has been developed and had excellent performance ...

Protein tyrosine kinase-7 (PTK7), a member of receptor tyrosine kinase superfamily initially identified as colon carcinoma kinase-4, is highly expressed in various human malignancies. Its expression ...

Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA ligand. Although the case ...

Heart failure remains a major source of late morbidity and mortality after myocardial infarction (MI). The temporospatial presence of activated fibroblasts in the injured myocardium predicts the ...

The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is overexpressed by ...

Journal of Nuclear Medicine October 2025, jnumed.125.270239; DOI: https://doi.org/10.2967/jnumed.125.270239 ...

Journal of Nuclear Medicine October 2025, jnumed.125.270215; DOI: https://doi.org/10.2967/jnumed.125.270215 ...

The aim of this work was to develop a theranostic method that allows prediction of prostate-specific membrane antigen (PSMA)–positive tumor volume after radioligand therapy (RLT) based on a ...